Executive interview – ASIT Biotech

Published on 16 July 2018

ASIT Biotech is a Belgian biotechnology company focused on late-stage clinical development of allergy immunotherapies (AITs). Its first product in Phase III is a grass pollen AIT with the advantages of a very short administration. ASIT’s AITs require only four treatment visits in 3 weeks to the allergist prior to the pollen season rather than visits for most of the year which are needed with other subcutaneous AITs, or over many years for sublingual AITs. CEO, Thierry Legon, discusses the advantages of ASIT’s technology, its strong patent position and the timing for its next Phase III study, and the potential for ASIT’s technology platform to generate AITs in other allergy indications.

Share this with friends and colleagues